Granules Consumer Health Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Granules Consumer Health Pharmaceutical Import Records from India — 8 Products, $110.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Granules Consumer Health — Pharmaceutical Importer Profile (2026) | 8 Products, $110.4M Trade | TransData Nexus

Granules Consumer Health

Pharmaceutical Importer · United States · Analgesics & Antipyretics Focus · $110.4M Total Trade · DGFT Verified

Granules Consumer Health is a pharmaceutical importer based in United States with a total trade value of $110.4M across 8 products in 4 therapeutic categories. Based on 2,267 verified import shipments from Indian Customs (DGFT) records, Granules Consumer Health is the #1 buyer in 3 products including Acetaminophen, Amino, Guaifenesin. Granules Consumer Health sources from 3 verified Indian suppliers, with Granules India Limited accounting for 96.7% of imports.

Granules Consumer Health — Import Portfolio & Supplier Network

Granules Consumer Health import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Granules Consumer Health?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Granules India Limited	$52.7M	1,352	96.7%
Granules Life Sciences Private Limited	$1.7M	35	3.2%
Softgel Healthcare Private Limited	$50.0K

What Formulations Does Granules Consumer Health Import?

Formulation	Value	Ships
Acetaminophen extended release tablets	$6.0M	120
Acetaminophen rapid release gelcaps	$1.4M	28
Extra strength acetaminophen USP 500MG	$1.2M	33
Acetaminophen extended-release tablets	$1.2M	26
Acetaminophen extended release tablets USP 650MG	$1.1M	28
Acetaminophen extended release tablets	$850.0K	17
Fexofenadine hydrochloride tablets USP 180MG	$653.9K	15
Apap rr gel500mg(gray	$500.0K	10
Cetirizine hydrochloride tablets USP	$466.2K	10
Acetaminophen 500MG and	$414.9K	13
Acetaminophen rapid release gelcaps 500MG (gray)	$392.3K	8
Guaifenesin extended release tablets	$360.2K	10
Guaifenesin extended release tablets 600MG	$359.1K	9
Fexofenadine hydrochloride tablets USP	$357.6K	9
Loratadine tablets USP 10MG	$325.0K	8

Granules Consumer Health imports 678 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Acetaminophen	Analgesics & Antipyretics	$46.6M	933	20.1%	1
2	Amino	Nutritional Supplements	$46.6M	933	14.5%	1
3	Guaifenesin	Respiratory & OTC	$5.8M	116	21.7%	1
4	Fexofenadine	Antihistamines & Allergy	$3.9M	78	3.6%	4
5	Cetirizine	Antihistamines & Allergy	$2.9M	65	1.6%	9
6	Loratadine	Antihistamines & Allergy	$2.1M	43	1.2%	7
7	Diphenhydramine	Antihistamines & Allergy	$1.8M	66	5.6%	5
8	Aspirin	Analgesics & Antipyretics	$668.0K	33	1.8%	9

Granules Consumer Health imports 8 pharmaceutical products across 4 categories into United States totaling $110.4M. The company is the #1 buyer for 3 products: Acetaminophen, Amino, Guaifenesin.

Granules Consumer Health — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Granules Consumer Health is a U.S.-based pharmaceutical importer specializing in over-the-counter (OTC) generic medications. Operating as the front-end division of Granules India Limited, the company focuses on providing high-quality, cost-effective alternatives to brand-name drugs. Headquartered in Manassas, Virginia, Granules Consumer Health plays a pivotal role in the U.S. pharmaceutical distribution network by manufacturing, packaging, and distributing OTC products to major retailers.

The company was established in 2014 and has since expanded its operations significantly. In March 2023, Granules Consumer Health inaugurated a state-of-the-art packaging facility in Manassas, Virginia, spanning over 79,000 square feet. This facility is equipped with advanced packaging lines and clean rooms, enabling the company to efficiently package and ship both prescription and OTC products across the U.S. market.

2Distribution Network

Granules Consumer Health's distribution network is centered around its Manassas, Virginia facility, which serves as the primary hub for packaging and shipping pharmaceutical products. The facility's strategic location facilitates efficient logistics and timely delivery to various regions within the United States. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's expansion efforts, including the $1.5 million investment in new manufacturing lines announced in October 2024, indicate a commitment to enhancing its distribution infrastructure.

3Industry Role

Granules Consumer Health operates as a pharmaceutical importer and distributor within the U.S. market. By sourcing generic OTC medications from its parent company, Granules India Limited, and other suppliers, the company serves as a key player in the pharmaceutical supply chain, ensuring the availability of affordable and high-quality medications to U.S. consumers. Its role encompasses the importation, packaging, and distribution of these products to major retailers, thereby contributing to the accessibility and affordability of healthcare in the United States.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Granules Consumer Health

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Granules Consumer Health's sourcing strategy exhibits a high degree of concentration, with a significant portion of its imports originating from Granules India Limited. This dependency on a single supplier could pose risks related to supply chain disruptions, such as production delays or regulatory challenges. However, the company's substantial investment in its own manufacturing facility in Virginia suggests a strategic move to mitigate such risks by enhancing control over production and distribution processes. The facility's successful U.S. FDA inspection in December 2025, which resulted in zero observations, further underscores the company's commitment to quality and regulatory compliance.

2Supply Chain Resilience

Granules Consumer Health's supply chain resilience is bolstered by its vertically integrated operations, particularly the establishment of its own manufacturing facility in Manassas, Virginia. This facility not only processes controlled substances and OTC products but also serves as a critical packaging and distribution site, enhancing the company's ability to manage production and mitigate potential disruptions. The facility's compliance with Good Manufacturing Practice (GMP) standards, as evidenced by the zero-observation FDA inspection in December 2025, reflects a strong commitment to quality and regulatory adherence.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, manufacturing, and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which sets forth requirements for drug approval, labeling, and manufacturing practices. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drugs and ensuring they meet safety and efficacy standards. For Indian generics to enter the U.S. market, they must undergo the Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the U.S. are stringent. Importers must ensure that their products comply with FDA regulations, including obtaining necessary approvals and certifications. Good Manufacturing Practice (GMP) certification is essential, with the FDA recognizing certifications from reputable authorities such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Additionally, wholesale distribution authorization is required, ensuring that distributors adhere to standards that guarantee the safety and efficacy of pharmaceutical products.

Granules Consumer Health — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Granules Consumer Health's focus on analgesics and antipyretics, nutritional supplements, and antihistamines aligns with prevalent health concerns in the U.S. market. The high demand for pain relief, fever reduction, and allergy management drives the importation of these products. By concentrating on these therapeutic areas, the company addresses significant consumer needs, positioning itself as a key supplier of essential OTC medications.

2Sourcing Profile

Granules Consumer Health's sourcing strategy emphasizes generic drug products, particularly those that offer cost-effective alternatives to brand-name medications. The company's preference for formulations that are widely used and in high demand, such as acetaminophen and ibuprofen, reflects a strategic approach to meet market needs efficiently. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a suitable source for these products.

3Market Positioning

Granules Consumer Health serves the U.S. retail pharmacy segment, supplying major retailers with OTC generic medications. By providing affordable and high-quality alternatives to brand-name drugs, the company enhances the accessibility of essential healthcare products to a broad consumer base. Its strategic focus on high-demand therapeutic areas further solidifies its position in the market.

Seller's Guide — How to Become a Supplier to Granules Consumer Health

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the U.S. market by partnering with Granules Consumer Health. To capitalize on this opportunity, suppliers must demonstrate compliance with FDA regulations, including GMP standards, and the ability to meet the company's quality and supply chain requirements. Additionally, offering products that align with Granules Consumer Health's focus on high-demand therapeutic areas can enhance the attractiveness of the partnership.

2Requirements & Qualifications

Indian exporters seeking to supply Granules Consumer Health and the U.S. market must obtain FDA approval for their products, which includes demonstrating bioequivalence for generics. They must also possess valid GMP certifications recognized by the FDA, such as EU GMP, WHO GMP, or PIC/S. Additionally, compliance with U.S. labeling requirements, including English language labeling and serialization mandates, is essential.

3How to Approach

Frequently Asked Questions — Granules Consumer Health

What products does Granules Consumer Health import from India?

Granules Consumer Health imports 8 pharmaceutical products across 4 categories. Top imports: Acetaminophen ($46.6M), Amino ($46.6M), Guaifenesin ($5.8M), Fexofenadine ($3.9M), Cetirizine ($2.9M).

Who supplies pharmaceuticals to Granules Consumer Health from India?

Granules Consumer Health sources from 3 verified Indian suppliers. The primary supplier is Granules India Limited (96.7% of imports, $52.7M).

What is Granules Consumer Health's total pharmaceutical import value?

Granules Consumer Health's total pharmaceutical import value from India is $110.4M, based on 2,267 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Granules Consumer Health focus on?

Granules Consumer Health imports across 4 categories. The largest: Analgesics & Antipyretics (42.9%), Nutritional Supplements (42.3%), Antihistamines & Allergy (9.6%).

Get Full Granules Consumer Health Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.